Chai Discovery
San Francisco AI drug-design company behind the Chai-3 model; announced a collaboration with Roche on Nov 6 2026.
Chai Discovery describes itself as an AI company building a computer-aided design suite for protein-based therapeutics. It is based in San Francisco and was founded in 2024 by Joshua Meier (co-founder and CEO), Jack Dent, Matthew McPartlon and Jacques Boitreaud. The company says it is backed by Index Ventures, Kleiner Perkins, Sequoia Capital, Dimension, Oak HC/FT, General Catalyst, OpenAI, Thrive Capital and Menlo Ventures; it gave no funding total or valuation in the release (all company statements).
Roche collaboration (Nov 6 2026)
Chai announced that Roche will use its AI models and platform in a number of drug discovery programs across Roche’s therapeutic areas. The release names no programs or targets and gives no financial terms, milestones or duration. It calls the deal the latest in a series of collaborations with large pharma companies in 2026 without naming the others (company claim, not verified here). Chai says its latest model, Chai-3, “achieves high target success rates and binding affinities, including to challenging targets”; the release gives no benchmarks, so treat that as a vendor claim.
Timeline
Every dated event in the wiki that involves Chai Discovery, newest first.
- Roche partners with Chai Discovery on AI protein design
Roche will use Chai's platform and its Chai-3 model across drug discovery programmes for protein-based therapeutics, following Chai's deal with Bristol Myers Squibb. Terms undisclosed; performance claims are Chai's.
Sources: Digital Health News, “Roche Partners with Chai Discovery to Leverage AI Models in Drug Discovery Programmes”
Connections
Chai Discovery and everything one link away. Drag to move, scroll to zoom, click a node to open it.Open in the full graph →
Sources
- BioSpace, “Chai Discovery Announces Collaboration with Roche in AI-Driven Drug Discovery”, Nov 6 2026 (Business Wire release)
- Digital Health News, “Roche Partners with Chai Discovery to Leverage AI Models in Drug Discovery Programmes”, Nov 6 2026